PHYTOCHEMICAL DRUG DISCOVERY FOR CENTRAL NERVOUS SYSTEM DISORDERS Understand herbal and plant-based treatments for chronic disorders with this groundbreaking work Due in part to the aging of the global population, disorders of the central nervous system have become an increasingly grave public health concern in recent years. Demand for pharmaceutical treatments has been correspondingly high, but there are many barriers to the successful development of effective synthetic drugs. Phytomedicines, or plant-based and herbal medicines, have proven to be an effective alternative, boasting lower toxicity and cost and higher efficacy, and one that demands greater research and broader-based practitioner knowledge. Phytochemical Drug Discovery for Central Nervous System Disorders meets this demand with a timely, clearly-structured guide. It thorough coverage presents a wide range of phytochemicals with potential as candidates for drug discovery, describing their sources, properties, and therapeutic efficacy. The result is a vital contribution to the ongoing fight against central nervous system (CNS) disorders. Phytochemical Drug Discovery for Central Nervous System Disorders readers will also find: Detailed treatment of CNS-active plant products, neuroprotective chemicals, plant-based nutraceutical products, and more Up-to-date information on FDA-approved drugs and existing plant-based products used to treat CNS disorders An authorial team featuring experts from across the globe Phytochemical Drug Discovery for Central Nervous System Disorders is essential for drug discovery scientists, drug developers, medicinal chemists, biochemists, and any researchers and professionals in the health care or pharmaceutical industries.

Nervous System Diseases: Advances in Research and Treatment: 2011 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Nervous System Diseases. The editors have built Nervous System Diseases: Advances in Research and Treatment: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Nervous System Diseases in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Nervous System Diseases: Advances in Research and Treatment: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

With addiction a key target for drug discovery efforts, this book fills an important and timely need for medicinal chemists who need to understand complex neuroscience issues. The author illustrates medicinal chemistry's prominent role in treating addiction and covers specific drugs of abuse including narcotics, stimulants, depressants, nicotine, and marijuana. • Interprets complex neuro- biological and pharmacological information, like the drug-reward system, for medicinal chemists • Emphasizes neurotransmitters and neurochemical mechanisms of addictive drugs • Pulls together information on the many potential drug targets for treating addiction • Stresses unique medicinal chemistry problems when describing pharmacology testing methods and drug development

Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.

Neurological Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for neurological disorders such as neurofibromatosis, Alzheimer's disease, Parkinson's disease, Huntington disease, ALS, and the epilepsies. Neurological Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the second volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, which is also available for purchase individually. - Clinical, academic, government and industry perspectives fostering integrated communication between principle participants at all stages of the drug discovery process - Critical evaluation of animal and translational models improving transition from drug discovery and clinical development - Emphasis on what results mean to the overall drug discovery process - Exploration of issues in clinical trial design and conductance in each therapeutic area

Glutamate is the most pervasive neurotransmitter in the central nervous system (CNS). Despite this fact, no validated biological markers, or biomarkers, currently exist for measuring glutamate pathology in CNS disorders or injuries. Glutamate dysfunction has been associated with an extensive range of nervous system diseases and disorders. Problems with how the neurotransmitter glutamate functions in the brain have been linked to a wide variety of disorders, including schizophrenia, Alzheimer's, substance abuse, and traumatic brain injury. These conditions are widespread, affecting a large portion of the United States population, and remain difficult to treat. Efforts to understand, treat, and prevent glutamate-related disorders can be aided by the identification of valid biomarkers. The Institute of Medicine's Forum on Neuroscience and Nervous System Disorders held a workshop on June 21-22, 2010, to explore ways to accelerate the development, validation, and implementation of such biomarkers. Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System: Workshop Summary investigates promising current and emerging technologies, and outlines strategies to procure resources and tools to advance drug development for associated nervous system disorders. Moreover, this report highlights presentations by expert panelists, and the open panel discussions that occurred during the workshop.

Nervous System Diseases—Advances in Research and Treatment: 2013 Edition is a ScholarlyEditions™ book that delivers timely, authoritative, and comprehensive information about Neuromuscular Diseases. The editors have built Nervous System Diseases—Advances in Research and Treatment: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Neuromuscular Diseases in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Nervous System Diseases—Advances in Research and Treatment: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Central Nervous System Diseases: New Insights for the Healthcare Professional: 2013 Edition is a ScholarlyEditions™ book that delivers timely, authoritative, and comprehensive information about Diagnosis and Screening. The editors have built Central Nervous System Diseases: New Insights for the Healthcare Professional: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Diagnosis and Screening in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Central Nervous System Diseases: New Insights for the Healthcare Professional: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

The Microbiology of Central Nervous System Infections, Volume 3, discusses modern approaches to the diagnosis, treatment and prophylaxis of central nervous system (CNS) infections. This new release is divided into five sections that cover treatment strategies, imaging, molecular diagnosis, management of CNS infections with metal nanoparticles, and prophylaxis of CNS infections, including bacterial, viral and fungal infections. The last section contains a chapter on transmissible spongiform encephalopathies and modern trends in its diagnosis and treatment. University teachers, medical practitioners, graduate and postgraduate students, researchers in microbiology, and those in the pharmaceutical and laboratory diagnostic industries will find the book very important. - Encompasses a broad range of central nervous system infections, including questions of etiology, pathogenesis, diagnosis, prognosis, treatment and prophylaxis - Written by highly professional and eminent surgeons, microbiologists and infectious disease specialists - Includes scientific understanding and practical guidelines, making it interesting for both research scientists and practitioners

As a guide for pharmaceutical professionals to the issues and practices of drug discovery toxicology, this book integrates and reviews the strategy and application of tools and methods at each step of the drug discovery process. • Guides researchers as to what drug safety experiments are both practical and useful • Covers a variety of key topics – safety lead optimization, in vitro-in vivo translation, organ toxicology, ADME, animal models, biomarkers, and –omics tools • Describes what experiments are possible and useful and offers a view into the future, indicating key areas to watch for new predictive methods • Features contributions from firsthand industry experience, giving readers insight into the strategy and execution of predictive toxicology practices